Recent advances in the treatment of opiate addiction

Clinical Neuroscience Research

Volumn 5, Issue 2-4, 2005, Pages 161-167

  Ling, Walter ^a   Compton, Peggy ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Addiction; Buprenorphine; Methadone; Opiates; Pharmacotherapy

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CLONIDINE; DIAMORPHINE; LEVACETYLMETHADOL; LOFEXIDINE; METHADONE; MORPHINE; NALTREXONE; NARCOTIC ANALGESIC AGENT; OPIATE; UNCLASSIFIED DRUG;

ARTICLE; ATTITUDE; CARDIOTOXICITY; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG LEGISLATION; DRUG MECHANISM; DRUG RESEARCH; DRUG SYNTHESIS; HEALTH CARE AVAILABILITY; HEALTH CARE POLICY; HEROIN DEPENDENCE; HUMAN; HYPOTENSION; MAINTENANCE THERAPY; NONHUMAN; OPIATE ADDICTION; POLITICS; PRIORITY JOURNAL; RESPIRATION DEPRESSION; SEDATION; SOCIAL PSYCHOLOGY; SOMNOLENCE; TABLET FORMULATION; UNITED STATES; WITHDRAWAL SYNDROME;

EID: 27944476926     PISSN: 15662772     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cnr.2005.08.012     Document Type: Article

References (86)

1. V.P. Dole M.E. Nyswander A medical treatment for diacetyl-morphine (heroin) addiction J Am Med Assoc 193 1965 646
2. The Medical and Surgical History of the Civil War, 1991. Wilmington, NJ: Broadfoot.
3. S. Graham-Mulhall Opium: The demon flower 1926 Montrose New York
4. R.P. Hobson Mankind's greatest affliction and gravest menace Narc Educ 1 1928 51-54
5. United States v Doremus, 1919. 249 U.S. 86.
6. Webb et al. v. United States, 1919. 249 U.S. 89.
7. D.F. Musto The American disease Origins of Narcotic Control 1987 Oxford University Press New York
8. M. Massing The fix 1998 University Press California
9. Joint Committee of the American Bar Association and the American Medical Association on Narcotic Drugs Drug addiction: Crime or disease? 1961 Indiana Press Bloomington
10. Task Force on Narcotics and Drug Abuse, President's Commission on Law Enforcement and Administration of Justice Task force report: Narcotics and drug abuse 1967 Washington DC GPO
11. J.H. Jaffe C. O'Keeffe From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States Drug Alcohol Depend 70 2 supple. 2003 3-11
12. Health and Human Services Opioid drugs in maintenance and detoxification treatment of opiate addiction. Substance abuse and mental health services Fed Regist 66 11 2001 4076-4102
13. Jaffe JH. The history and current status of opiate agonist treatment. In: Effective medical treatment of heroin addiction. NIH consensus development conference; 1997, 19-25.
14. L.N. Robins J.E. Helzer D.H. Davis Narcotics use in southeast Asia and afterward. An interview study of 898 Vietnam returnees Arch Gen Psychiatry 32 8 1975 955-961
15. L.N. Robins S. Slobodyan Post-Vietnam heroin use and injection by returning US veterans: Clues to preventing injection today Addiction 98 8 2003 1053-1060
16. M.J. Kreek F.J. Vocci History and current status of opioid maintenance treatments: Blending conference sessions J Subst Abuse Treat 23 2002 93-105
17. S.P. Molinari J.R. Cooper D.J. Czechowicz Federal regulation of clinical practice in narcotic addiction treatment: Purpose, status and alternatives J Law Med Ethics 22 1994 231-239
18. R.A. Rettig A. Yarmolinsky Federal regulation of methadone treatment 1995 Institute of Medicine National Academy Press Washington DC
19. Institute of Medicine Bridging the gap between practice and research: forging partnerships with community-based drug and alcohol treatment Nat Acad Sci 1998
20. W. Ling R.A. Rawson M.D. Anglin Pharmacology, practice, and politics: A tale of two opiate pharmacotherapies in: J.L. Sorensen R.A. Rawson J. Guydish J.E. Zweben editor Drug abuse treatment through collaboration: practice and research partnerships that work 2003 American Psychological Association Washington, DC 107-119
21. S. Archer Historical perspective on the chemistry and development of naltrexone in; R.E. Willette G. Barnet editors National institute on drug abuse monogNaph series 28: Narcotic antagonists: naltrexone pharmacochemistry and sustained-release preparations National institute on drug abuse monograph series 1980 Rockville Maryland 3-10
22. W.R. Martin D.R. Jasinski P.A. Mansley Naltrexone, an antagonist for the treatment of heroin dependence Arch Gen Psych 28 1973 784-791
23. S.D. Comer E.D. Collins H.D. Kleber E.S. Nuwayser J.H. Kerrigan M.N. Fischm Depot naltrexone: Long-lasting antagonism of the effects of heroin in humans Psychopharmacology 159 4 2002 351-360
24. S.D. Comer M.A. Sullivan E. Yu et al. Effectiveness of an injectable, sustained-release, depot formulationof naltrexone in the treatment of opioid dependence 2004 Australian Professional Society on Alcohol and other Drugs (APSAD) Fremantle, WA
25. A. Umbricht I.D. Montoya D.R. Hoover C.T. Demuth C.T. Chiang K.L. Preston Naltrexone shortened opioid detoxification with buprenorphine Drug Alcohol Depend 56 1999 181-190
26. C.B. Tornay B. Favrat M. Monnat et al. Drug Alcohol Depend 69 2003 283-288
27. C.A.J. De Jong R.J.F. Laheij P.F.M. Krabbe General anaesthesia does not improve outcome in opioid antagonist detoxification treatment: A randomized controlled trial Addiction 100 2 2005 206-215
28. Gowing L, Ali R, White J. Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal [Cochrane Review]. The Cochrane Library, Issue 4, 2002.
29. P.F. Krabbe J.P. Koning N. Heinen R.J. Laheij R.M. van Cauter C.A.J. de Jong Rapid detoxification from opioid dependence under general anaesthesia versus standard methadone tapering: Abstinence rates and withdrawal distress experiences Addict Biol 8 2003 351-358
30. R. White R. Alcorn C. Feinmann Two methods of detoxification from opiates: An open-label comparison of lofexidine and buprenorphine Drug Alcohol Depend 65 2001 77-83
31. Substance Abuse and Mental Health Services Administration Opioid drugs in the maintenance and detoxification treatment of opiate addiction: Addition of buprenorphine and buprenorphine combination to list of approved opioid treatment medications Fed Regist 68 2003 27937-27939
32. A. Cowan J.W. Lewis I.R. MacFarlane Agonist and antagonist properties of buprenorphine, a new antinociceptive agent Br J Pharmacol 60 1977 537-545
33. W.G. Edge G.M. Cooper M. Morgan Analgesic effects of sublingual buprenorphine Anaesthesia 34 1979 463-467
34. I. Lizasoain J.C. Leza P. Lorenzo Buprenorphine: Bell-shaped dose-response curve for its antagonist effects Gen Pharmacol 22 1991 297-300
35. W.R. Martin C.G. Eades J.A. Thompson R.E. Huppler P.E. Gilbert The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog JPET 197 1976 517-532
36. W.R. Lange P.J. Fudala E.M. Dax R.E. Johnson Safety and side-effects of buprenorphine in the clinical management of heroin addiction Drug Alcohol Depend 26 1990 19-28
37. S.L. Walsh K.L. Preston M.L. Stitzer E.J. Cone G.E. Bigelow Clinical pharmacology of buprenorphine: Ceiling effects a high doses Clin Pharmacol Ther 55 1994 569-580
38. S.L. Walsh T. Eissenberg The clinical pharmacology of buprenorphine: Extrapolating from the laboratory to the clinic Drug Alcohol Depend 70 2 supple. 2003 S13-S28
39. W.K. Bickel M.L. Stitzer G.E. Bigelow I.A. Liebson D.R. Jasinski R.E. Johnson Buprenorphine: Dose-related blockade of opioid challenge effects in opioid dependent humans J Pharmac Exp Ther 247 1988 47-53
40. M.I. Rosen E.A. Wallace T.J. McMahon et al. Buprenorphine: Duration of blockade of effects of intramuscular morphine Drug Alcohol Depend 35 1994 141-149
41. S.K. Teoh N.K. Mello J.H. Mendelson et al. Buprenorphine effects on morphine- and cocaine-induced subjective responses by drug-dependent men J Clin Pharmacol 14 1994 15-27
42. P.J. Fudala J.H. Jaffe E.M. Dax R.E. Johnson Use of buprenorphine in the treatment of opioid addiction, II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal Clin Pharmacol Ther 47 1990 525-534
43. L. Amass W.K. Bickel S.T. Higgins J.R. Hughes A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification J Addict Dis 13 1988 33-45
44. R.E. Johnson T. Eissenberg M.L. Stitzer E.C. Strain I.A. Liebson G.E. Bigelow A placebo-controlled clinical trial of buprenorphine as a treatment for opioid dependence Drug Alcohol Depend 40 1995 17-25
45. P.J. Fudala R.E. Johnson E. Bunker Abrupt withdrawal of buprenorphine following chronic administration Clin Pharmacol Ther 45 1989 186
46. D.R. Jasinski J.S. Pevnick J.D. Griffith Human pharmacology and abuse potential of the analgesic buprenorphine Arch Gen Psychiatry 35 1978 501-516
47. N.K. Mello J.H. Mendelson Buprenorphine suppresses heroin use by heroin addicts Science 207 1980 657-659
48. N.K. Mello J.H. Mendelson J.C. Kuehnle Buprenorphine effects on human heroin self-administration: An operant analysis J Pharmac Exp Ther 223 1982 30-39
49. W. Ling D.R. Wesson Clinical efficacy of buprenorphine: Comparisons to methadone and placebo Drug Alcohol Depend 70 2 supple. 2003 S49-S58
50. C.N. Chiang R.L. Hawks Pharmacokinetics of the combination tablet of buprenorphine and naloxone Drug Alcohol Depend 70 2 supple. 2003 S39-S48
51. K. Ajir C.N. Chiang A. Huber W. Ling Pharmacokinetics of liquid vs. tablet buprenorphine in; L.S. Harris editors Problems of drug dependence Proceedings of the 61st annual meeting, CPDD, inc, NIDA research monograph series no. 180 1999 US GPO Washington DC 160
52. R.P. Nath R.A. Upton E.T. Everhart et al. Buprenrophine pharmacokinetics: Relative bioavailability of sublingual tablet and liquid formulations J Clin Pharmacol 39 1999 619-623
53. P.J. Fudala E. Yu W. Macfadden C. Boardman C.N. Chiang Effects of buprenorphine and naloxone in morphine-stabilized opiate addicts Drug Alcohol Depend 50 1998 1-8
54. D.S. Harris R.T. Jones S. Welm R.A. Upton E. Lin J. Mendelson Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine Drug Alcohol Depend 61 2000 85-94
55. J. Mendelson R.T. Joners I. Fernandez S. Welm A.K. Melby M.J. Baggott Buprenorphine and Naloxone interactions in opiate-dependent volunteers Clin Pharmacol Ther 60 1996 105-114
56. K.L. Preston G.E. Bigelow I.A. Liebson Buprenorphine and naloxone alone and in combination in opioid-dependent humans Psychopharmacology 94 1988 484-490
57. K.B. Stoller G.E. Bigelow S.L. Walsh E.C. Strain Effects of buprenorphine/Naloxone in opioid-dependent humans Psychopharmacology 154 2001 230-242
58. E.C. Strain K. Stoller S.L. Walsh G.E. Bigelow Effects of buprenorphine versus buprenorphine/Naloxone tablets in non-dependent opioid abusers Psychopharmacology 148 2000 374-383
59. L.L. Weinhold K.L. Preston M. Farre I.A. Liebson G.E. Bigelow Buprenorphine alone and in combination with naloxone in non-dependent humans Drug Alcohol Depend 30 1992 263-274
60. J. Mendelson R.T. Jones S. Welm et al. Buprenrophione and Naloxone combinations: The effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers Psychopharmacology 141 1999 37-46
61. J. Mendelson R.T. Jones Clinical and pharmacological evaluation of buprenorphine and Naloxone combinations: Why the 4:1 ratio for treatment? Drug Alcohol Depend 70 2 supple. 2003 S29-S38
62. Auriacombe, M., Franques, P., Tignol, J., 2001. Deaths attributable to methadone vs. buprenorphine in France. 285, 45.
63. L.N. Bell G. Bammer A randomized controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal Addiction 97 2002 1395-1404
64. J. Kakko K.D. Svanborg M.J. Kreek M. Heillig 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo-controlled trial Lancet 361 2003 662-668
65. S. Petitjean R. Stohler J.J. Deglon et al. Double-blind randomized trial of buprenorphine and methadone in opiate dependence Drug Alcohol Depend 62 2001 97-104
66. G. Vidal-Trecan I. Varescon N. Nabet A. Boissonnas Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France Drug Alcohol Depend 69 2003 175-181
67. C.L. Breen S.J. Harris N. Lintzeris et al. Cessation of methadone maintenance treatment using buprenorphine: Transfer from methadone to buprenorphine and subsequent buprenorphine reductions Drug Alcohol Depend 71 2003 49-55
68. N. Lintzeris J. Bell G. Bammer D.J. Jolley L. Rushworth A randomized controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal Addiction 97 2002 1395-1404
69. R.P. Mattick R. Ali J.M. White S. O'Brien S. Wolk C. Danz Buprenorphine versus methadone maintenance therapy: A randomized double-blind trial with 405 opioid-dependent patients Addiction 98 2003 441-452
70. R.P. Mattick J. Kimber C. Breen M. Davoli Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence Cochrane Database Syst Rev 3 2004 CD002207
71. A.E. Gibson C.M. Doran J.R. Bell A. Ryan N. Lintzeris A comparison of buprenorphine treatment in clinic and primary care settings: A randomized trial Med J Aus 179 2003 38-42
72. P.G. O'Connor A. Oliveto J.M. Shi et al. A pilot study of primary-care-based buprenorphine maintenance for heroin dependence Am J Drug Alcohol Abuse 22 1996 523-531
73. P.G. O'Connor A. Oliveto J.M. Shi et al. A randomized clinical trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic Am J Med 105 1998 100-105
74. R. Rosenbeck T.R. Kosten Buprenorphine for opiate addiction: Potential economic impact Drug Alcohol Depend 63 2001 253-262
75. T.P. Bridge P.J. Fudala S. Herbert D.B. Leiderman Safety and health considerations related to the use of buprenorphine/Naloxone as an office-based treatment for opioid dependence Drug Alcohol Depend 70 2 supple. 2003 S79-S86
76. A.I. Leshner Accessing opiate dependence treatment medications: buprenorphine products in an office based setting Drug Alcohol Depend 70 2 supple. 2003 S103-S104
77. P.J. Fudala T.P. Bridge S. Herbert et al. Buprenorphine/Naloxone Collaborative Study Group, Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone N Engl J Med 349 2003 949-958
78. L. Amass W. Ling T.E. Freese C. Reiber J.J. Annon A.J. Cohen D. McCarty M.S. Reid J.r. Brown S. L C.C. Clark D.M. Ziedonis J. Krejci S. Stine T. Winhusen G. Brigham D. Babcock J.A. Muir B.J. Buchan T. Horton Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience Am J Addict 13 2004 S42-S66
79. Ling W, Amass L, Shoptaw S, Annon JJ, Babcock D, Brigham, G, Harrer, J, Muir J, Buchan B, Orr D, Woody G, Krejci J. and the Buprenorphine Study Protocol Group. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network in submission.
80. W. Ling D. Smith Buprenorphine: Blending practice and research J Subst Abuse Treat 23 2002 87-92
81. M.I. Rosen T.R. Kosten Buprenorphine: Beyond methadone Hosp Commun Psychiatry 42 1991 347-349
82. M. Meadows Prescription drug abuse: FDA and SAMHSA join forces FDA Consum 37 2003 36
83. A. Umbricht D.R. Hoover M.J. Tuucker J.M. Leslie R.E. Chaisson K.L. Preston Opioid detoxification with buprenorphine, clonidine, or methadone in hospitatized heroin-dependent patients with HIV infection Drug Alcohol Depend 69 2003 263-272
84. P.G. Barnett G.S. Zaric M.L. Brandeau The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States Addiction 96 2001 1267-1278
85. R.E. Johnson E.C. Strain L. Amass Buprenorphine: How to use it right Drug Alcohol Depend 70 2 supple. 2003 S59-S78
86. V.P. Dole M.E. Nyswander M.J. Kreek Narcotic blockade Arch Int Med 118 1966 304-309